AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
A Tale of Divergence: GLP-1 Agonists Improve Outcomes in HFpEF but Not HFrEF - A Systematic Review and Meta-Analysis
By Reddi S, Rathi S
Background: Glucagon-like peptide receptor agonists (GLP-1 RAs) have demonstrated cardiovascular (CV) benefits in type 2 diabetes and obesity. However, their effects appear to diverge based on heart failure (HF) subtype - demonstrating favorable effects in HF with preserved ejection fraction (HFpEF), and neutral-to-unfavorable effects in heart failure with reduced ejection (HFrEF). Methods: A literature search on PubMed, Cochrane, and Web of Science, was conducted to identify randomized controlled trials (RCTs) comparing GLP-1 RAs with placebo in patients with established HF. The primary outcome was worsening HF events. Secondary outcomes included the composite of HF worsening events or CV death, change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), 6-minute walk distance (6MWD), NT-proBNP, body weight, and adverse events. Data were pooled using random-effects models. Results: Fourteen RCTs encompassing > 30,000 patients were included: 7 HFpEF analyses (STEP-HFpEF, STEP-HFpEF DM, SUMMIT, SELECT, FLOW, SOUL, EXSCEL subgroups), 5 HFrEF analyses (FIGHT, LIVE, Albiglutide HFrEF, SELECT and SOUL subgroups), and 2 mixed-HF analyses (LEADER, Harmony Outcomes subgroups). In HFpEF, GLP-1 RAs significantly reduced HF worsening events (HR 0.59, 95% CI 0.41-0.82; p = 0.002) and the composite of HF worsening or CV death (HR 0.69, 95% CI 0.53-0.89; p=0.005), with consistent benefits across semaglutide (STEP-HFpEF: HR 0.08; SELECT HFpEF: HR 0.75; SOUL HFpEF: HR 0.59), tirzepatide (SUMMIT: HR 0.62), and oral semaglutide. HFpEF patients also demonstrated improvements in KCCQ-CSS (+7.4 points, 95% CI 5.5-9.3), 6MWD (+17.6 m, 95% CI 11.9-23.3), and NT-proBNP (ratio 0.82-0.85), body weight (-8.4% to -11.6%), and CRP (ratio 0.61-0.64). In contrast, HFrEF trials showed no benefit for worsening HF (HR 1.23, 95% CI 0.89-1.69). FIGHT demonstrated numerically increased HF rehospitalization (HR 1.30) particularly in NYHA III-IV (IRR 1.86; 95% CI 1.21-2.85), and LIVE showed increased serious cardiac adverse events (10% vs 3%; p=0.04). The SOUL HFrEF subgroup confirmed no benefit (HR 0.98). Gastrointestinal adverse events were the leading cause of treatment discontinuation across both subtypes (RR 3.12, 95% CI 1.28-7.63). Conclusions: Incretin-based therapies produce robust clinical, functional, and biomarker benefits in HFpEF - reducing HF by 41% and improving symptoms, exercise capacity, and inflammation - but showing no benefit, and potential harm in HFrEF. These findings support GLP-1 RAs as targeted therapies for the obesity-related HFpEF phenotype and underscore the need for dedicated outcome trials in HFrEF.